Featured ArticlesGlobal Health

Is the Coronavirus (COVID-19) Pandemic an Indication to Temporarily Modify Dermatological Management Plans?

By March 30, 2020April 29th, 2020No Comments

Dermatology News

Featured Article

Dermatologist looking at skin

"Is the Coronavirus (COVID-19) Pandemic an Indication to Temporarily Modify Dermatological Management Plans?"

While the world lives under the shadow of the novel coronavirus (COVID-19) pandemic, dermatologists wonder if the current situation calls for a temporary change in the management of skin conditions.

Immunosuppressive drugs are used ubiquitously in the modern treatment of inflammatory and autoimmune skin diseases like psoriasis, bullous diseases, connective tissue diseases, and many others. Treatment of these conditions is based on the suppression of the patient’s immune system using steroids, steroid-sparing drugs, and biological agents.1
“The use of immunosuppressive to treat these conditions can amplify this effect, and it might leave the patient vulnerable to more serious complications should an infection with the novel coronavirus be established. Hence, it may be wise to restrict temporarily the use of immunosuppressive agents including systemic steroids, steroid-sparing agents, and biologics in dermatology daily practice until more evidence is avilable about their safety in the current pandemic.6 As a relates point, the International Psoriasis Council declared an urgent statement on March 11, 2020 that the physician should be alert to the potentially harmful effects of COVID-19 infection on patients with psoriasis and to immediately discontinue or postpone immunosuppressant medications for psoriasis patients diagnosed with COVID-19 disease.”

As the declaration of the novel coronavirus as a pandemic by the WHO is a trending topic nowadays, dermatologists around the world view with concern the impact of this pandemic on their daily practice.

Read Full Article Now

You May Also Like

Journal of Drugs in Dermatology JDD featuring Dr. Jacob Beer in JDD Re:View, a discussion of JDD articles and specific topics. Breakthroughs in atopic dermatitis are redefining treatment from the inside out. Discover how new data on race, microbes, and patient preferences are transforming the way we think about AD.Atopic DermatitisFeatured ArticlesJDD Re:ViewLatest NewsSkin of ColorThe Latest
October 31, 2025

JDD Re:View With Dr. Beer. Atopic Dermatitis Advances: What Every Clinician Should Know in 2025

Breakthroughs in atopic dermatitis are redefining treatment from the inside out. Discover how new data on race, microbes, and patient preferences are transforming the way we think about AD. In…
Journal of Drugs in Dermatology JDD Article About Skin Barrier Benefits of a Natural Moisturizing Factor and Lipids-Based Moisturizer for Clinically Sensitive SkinFeatured ArticlesLatest NewsSkincareThe Latest
October 30, 2025

Skin Barrier Benefits of a Natural Moisturizing Factor and Lipids-Based Moisturizer for Clinically Sensitive Skin

Barrier boost with benefits -  new topical cream raises filaggrin, hyaluronic acid and lipids while improving tolerability A novel topical cream moisturizer produced meaningful biological and clinical improvements in both…
Journal of Drugs in Dermatology JDD Article About An Exosome Regenerative Complex Plus Microneedling Promotes Hair Growth in Subjects With Self-Perceived Thinning HairFeatured ArticlesHairLatest NewsThe Latest
October 29, 2025

An Exosome Regenerative Complex Plus Microneedling Promotes Hair Growth in Subjects With Self-Perceived Thinning Hair

Exosome complex after microneedling shows promising hair‑regrowth signals in a 30‑patient series In a 30‑subject study (15 men, 15 women; mean age 50.2 years) treated with an Exosome Regenerative Complex+…

Leave a Reply